Rimini Street Announces New Management Console for Rimini Connect™ Suite of Interoperability Solutions 
HKTDC and Hang Seng Bank’s InnoClub Recognises and Supports Outstanding GBA Start-ups Eton Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Financial Results
DEER PARK, Ill., March 16, 2021 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (Nasdaq: ETON), an…
Berkeley Lights to Participate in the KeyBanc Life Sciences & MedTech Investor Forum
EMERYVILLE, Calif., March 16, 2021 (GLOBE NEWSWIRE) — Berkeley Lights, Inc. (Nasdaq: BLI), a leader…
Cyclacel Pharmaceuticals Announces Closing of $14.5 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
BERKELEY HEIGHTS, N.J., March 16, 2021 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;…
Motus GI Reports Fourth Quarter 2020 Financial Results and Provides Corporate Update
Signed new 12-month committed volume contracts with two prominent U.S. medical centers Reported progress on…
NTG Nordic Transport Group A/S – Notice to convene the Annual General Meeting 2021
Company announcement no 13 – 2116 March 2021 NTG Nordic Transport Group A/S – Notice…
Zealand Pharma convenes its Annual General Meeting 2021
Company Announcement – No. 13 / 2021 Zealand Pharma convenes its Annual General Meeting 2021…
Cue Biopharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
Evaluated initial observations in CUE-101 Phase 1 monotherapy dose escalation clinical trial for treatment of…
Kymera Therapeutics Appoints Elena Ridloff, CFA, to Board of Directors
WATERTOWN, Mass., March 16, 2021 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage…
Bespoke Extracts Names MMA Fighter Mike “Platinum” Perry as New Brand Ambassador
Company Also Announces that Pre-Orders for New Manuka Honey + CBD Products Now Being Accepted…
Alliance for Regenerative Medicine Annual Report Highlights Record Sector Growth and Resilience in 2020
ALLIANCE FOR REGENERATIVE MEDICINE ANNUAL REPORT HIGHLIGHTS RECORD SECTOR GROWTH AND RESILIENCE IN 2020 Sector…
NABP Reaffirms Support for COVID-19 Vaccines
MOUNT PROSPECT, IL, March 16, 2021 (GLOBE NEWSWIRE) — The National Association of Boards of…
Cannalogue Now Accepting Requests for Clinical Trials and Research with Medical CBD
Medical cannabis provider aims to accelerate research efforts throughout North America TORONTO, March 16, 2021…
CohBar Nominates CB5138 Analog as Lead Clinical Candidate for Idiopathic Pulmonary Fibrosis and other Fibrotic Diseases
MENLO PARK, Calif., March 16, 2021 (GLOBE NEWSWIRE) — CohBar, Inc. (NASDAQ: CWBR), a clinical…
Adaptive Research Appoints Mark Tsuchiyose, MD as Vice President, Clinical Affairs and Therapeutic Head, Gastroenterology, and Dhira Khosla, DO as Vice President, Strategic Clinical Partnerships, Positioning Company to Drive Continued Growth
SAN FRANCISCO, March 16, 2021 (GLOBE NEWSWIRE) — Adaptive Research Inc. (the “Company”), a healthcare…
Nurix Therapeutics Announces Collaboration for the Discovery of Novel Drugs to Treat Pediatric Cancers
Research focused on targeted degradation of MYCN for the potential treatment of neuroblastoma and medulloblastomaProgram…
BrightInsight and AstraZeneca Collaborate to Enhance Disease Management
BrightInsight Accelerates Time to Market for the AstraZeneca AMAZE Disease Management Platform Within a Regulatory-Compliant…
Arch Biopartners Receives Health Canada Authorization to Amend Phase II Trial Protocol for LSALT Peptide
TORONTO, March 16, 2021 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX…
Advaxis Reports First Quarter Ended January 31, 2021 Financial Results and Provides a Business Update
Continued enrollment in expanded ADXS-503 HOT program in NSCLC to explore potential to enhance and/or…
Adagene Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126, Lead SAFEbody™ Program
SAFEbody technology enables precision masking of antibodies for enhanced safety SAN FRANCISCO and SUZHOU, China,…
Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 ALIGN Study of Atrasentan for Patients with IgA Nephropathy
Phase 2 AFFINITY Trial of Atrasentan for Patients with Glomerular Diseases Also on Track to…